INSULET CORP (PODD) Stock Price & Overview

NASDAQ:PODD • US45784P1012

240.84 USD
-2.05 (-0.84%)
Last: Mar 5, 2026, 11:10 AM

The current stock price of PODD is 240.84 USD. Today PODD is down by -0.84%. In the past month the price decreased by -3.32%. In the past year, price decreased by -3.54%.

PODD Key Statistics

52-Week Range230.05 - 354.88
Current PODD stock price positioned within its 52-week range.
1-Month Range236.51 - 275.1
Current PODD stock price positioned within its 1-month range.
Market Cap
16.943B
P/E
48.46
Fwd P/E
37.99
EPS (TTM)
4.97
Dividend Yield
N/A

PODD Stock Performance

Today
-0.84%
1 Week
-2.11%
1 Month
-3.32%
3 Months
-20.23%
Longer-term
6 Months -30.29%
1 Year -3.54%
2 Years +41.71%
3 Years -23.85%
5 Years -6.91%
10 Years +632.48%

PODD Stock Chart

INSULET CORP / PODD Daily stock chart

PODD Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to PODD. When comparing the yearly performance of all stocks, PODD is a bad performer in the overall market: 80.21% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
PODD Full Technical Analysis Report

PODD Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to PODD. Both the health and profitability get an excellent rating, making PODD a very profitable company, without any liquidiy or solvency issues.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PODD Full Fundamental Analysis Report

PODD Earnings

On February 18, 2026 PODD reported an EPS of 1.55 and a revenue of 783.80M. The company beat EPS expectations (4.5% surprise) and missed revenue expectations (-0.03% surprise).

Next Earnings DateMay 6, 2026
Last Earnings DateFeb 18, 2026
PeriodQ4 / 2025
EPS Reported$1.55
Revenue Reported783.8M
EPS Surprise 4.50%
Revenue Surprise -0.03%
PODD Earnings History

PODD Forecast & Estimates

34 analysts have analysed PODD and the average price target is 363.98 USD. This implies a price increase of 51.13% is expected in the next year compared to the current price of 240.84.

For the next year, analysts expect an EPS growth of 27.55% and a revenue growth 20.5% for PODD


Analysts
Analysts84.71
Price Target363.98 (51.13%)
EPS Next Y27.55%
Revenue Next Year20.5%
PODD Forecast & Estimates

PODD Groups

Sector & Classification

PODD Financial Highlights

Over the last trailing twelve months PODD reported a non-GAAP Earnings per Share(EPS) of 4.97. The EPS increased by 49.25% compared to the year before.


Income Statements
Revenue(TTM)2.71B
Net Income(TTM)247.10M
Industry RankSector Rank
PM (TTM) 9.12%
ROA 7.75%
ROE 16.31%
Debt/Equity 0.61
Chartmill High Growth Momentum
EPS Q2Q%34.78%
Sales Q2Q%31.18%
EPS 1Y (TTM)49.25%
Revenue 1Y (TTM)30.73%
PODD financials

PODD Ownership

Ownership
Inst Owners101.26%
Shares70.35M
Float70.13M
Ins Owners0.29%
Short Float %2.16%
Short Ratio1.6
PODD Ownership

PODD Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.32196.666B
ISRG INTUITIVE SURGICAL INC48.05177.984B
SYK STRYKER CORP24.65146.042B
BSX BOSTON SCIENTIFIC CORP20.26107.089B
IDXX IDEXX LABORATORIES INC41.9151.799B
EW EDWARDS LIFESCIENCES CORP28.1249.453B
BDX BECTON DICKINSON AND CO10.7348.859B
RMD RESMED INC20.6237.738B
GEHC GE HEALTHCARE TECHNOLOGY15.3636.013B
DXCM DEXCOM INC28.2128.433B
ZBH ZIMMER BIOMET HOLDINGS INC11.0318.976B
HOLX HOLOGIC INC15.0316.893B

About PODD

Company Profile

PODD logo image Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 3,900 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.

Company Info

INSULET CORP

100 Nagog Park

Acton MASSACHUSETTS 01720 US

CEO: Shacey Petrovic

Employees: 3900

PODD Company Website

PODD Investor Relations

Phone: 19786007000

INSULET CORP / PODD FAQ

Can you describe the business of INSULET CORP?

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 3,900 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.


What is the current price of PODD stock?

The current stock price of PODD is 240.84 USD. The price decreased by -0.84% in the last trading session.


Does INSULET CORP pay dividends?

PODD does not pay a dividend.


How is the ChartMill rating for INSULET CORP?

PODD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.


What sector and industry does INSULET CORP belong to?

INSULET CORP (PODD) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


Can you provide the ownership details for PODD stock?

You can find the ownership structure of INSULET CORP (PODD) on the Ownership tab.